Our Science

Our Science : Drug Discovery Platforms : Compound Archives

Structural novelty and drug-like properties are key drivers for the collection

At FORMA, the compounds in our library are part of a continuously evolving collection that is refined and enhanced by data generated in our ongoing discovery programs. FORMA owns a proprietary collection of diverse, chemically pure, drug-like molecules for our high-throughput screening initiatives. In addition to the molecules that are produced to support of each particular target or target family (focused libraries), the library consists of distinct series of compounds. Structural novelty and drug-like properties are key drivers for including compounds in the collection, and their designs are assisted by in silico evaluation of a broad variety of physical and biological parameters. The series of compounds in our collection are:

Typically, our collection compounds are produced in sufficient quantities for rapid follow-up of confirmed screening hits. This infrastructure investment has enabled us to reduce typical follow-up times several-fold.